Summary & Overview
HCPCS Level II S0148: Injection, Pegylated Interferon Alfa-2b, 10 mcg
HCPCS Level II code S0148 designates the administration of pegylated interferon alfa-2b, 10 mcg. This injectable biologic is used in specific antiviral and immunomodulatory treatment regimens; accurate coding matters for clinical documentation, billing compliance, and national reimbursement consistency. The code is relevant to outpatient and ambulatory infusion settings where injectable therapies are administered.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, the typical sites of service, and which payers are commonly involved. The publication outlines benchmarking and coverage context, notes common billing modifiers and administrative considerations, and provides clinical context for when a pegylated interferon alfa-2b injection may be billed.
The content that follows offers national-level guidance on documentation elements tied to S0148, payer coverage patterns, and benchmarks where available. Data not available in the input is noted where applicable. This summary is intended for billing professionals, coding auditors, and clinicians who need a clear, national perspective on HCPCS Level II code S0148.
Billing Code Overview
HCPCS Level II code S0148 describes injection, pegylated interferon alfa-2b, 10 mcg. This billing code represents administration of a pegylated form of interferon alfa-2b in a 10 microgram dose.
Service Type: Injectable medication administration
Typical Site of Service: Outpatient clinic or physician office, infusion center, or other ambulatory care setting
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic viral infection (for example, certain hepatitis B or off-label oncology indications) under specialist care who requires supervised administration of a long-acting, pegylated interferon alfa-2b injection. The patient presents to an outpatient infusion or injection clinic, specialty pharmacy clinic, or an ambulatory clinic staffed by a hematology/oncology or infectious disease provider. Prior to the visit, the provider documents indication, baseline blood counts and liver function tests, and a medication reconciliation. At the visit the nurse verifies informed consent, reviews allergies, inspects the injection site, prepares S0148 (Injection, pegylated interferon alfa-2b, 10 mcg) per manufacturer and institutional protocol, and administers subcutaneously. Observation for acute adverse reactions occurs for a brief period; the visit note documents lot number, expiration, route, dose, and injector. Subsequent follow-up visits monitor laboratory response, adverse effects (flu-like symptoms, cytopenias, thyroid dysfunction, mood changes), and dosing intervals. Billing uses S0148 for the drug product; appropriate HCPCS modifiers (for example, those indicating professional/technical circumstances, discarded drug, or service disruptions) are appended as clinically applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |